Sinonasal mucosal melanoma (SNMM) is a rare tumor, comprising less than 10% of sinonasal malignancies. SNMM most frequently occurs in the nasal cavity (70%) and maxillary sinus (14%), typically as black patches.
Conferences
2020 Meeting on Cutaneous Malignancies Will Address Next Steps For Immunotherapy
Treatment with immunotherapy has become ingrained in the standard of care for treating patients with melanoma, but investigators continue to research new combinations and treatment strategies that can improve patients outcomes.
Tel Aviv University’s Prof. Carmit Levy receives Young Investigator Award from SMR
Tel Aviv University’s Prof. Carmit Levy received the prestigious Young Investigator Award at the 16th International Congress of the Society for Melanoma Research, held November 20-23 in Salt Lake City, Utah, for her “contributions to melanoma research that significantly exceeded the average for this career stage."
Large SPORE Grant Focuses on Developing Biomarkers to Predict Melanoma Immunotherapy Treatment Outcomes
The National Cancer Center Institute (NCI) has awarded NYU Langone Health a 5-year, $11 million grant to develop better tools to predict which patients with advanced melanoma will benefit from immune checkpoint inhibitors. The Ronald O. Perelman Department of Dermatology and Perlmutter Cancer Center are using the grant for four distinct and promising projects.